NRIX Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 87% planned / 13% discretionary
Largest single sale: $580.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Ring Christine 2 fills | Chief Legal Officer | Sell 10b5-1 | 5,787 | $25.76 | $149.1K | 9,510 −37.8% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell 10b5-1 | 1,452 | $25.47 | $37.0K | 117,227 −1.2% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell 10b5-1 | 4,356 | $25.00 | $108.9K | 117,227 −3.6% of holding | |
| van Houte Hans 2 fills | Chief Financial Officer | Sell 10b5-1 | 4,761 | $24.36 | $116.0K | 43,133 −9.9% of holding | |
| Hansen Gwenn 2 fills | Chief Scientific Officer | Sell 10b5-1 | 4,111 | $24.36 | $100.1K | 119,838 −3.3% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 16,589 | $23.05 | $382.4K | 9,110 −64.6% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell | 3,847 | $23.38 | $90.0K | 121,338 −3.1% of holding | |
| Ring Christine | Chief Legal Officer | Sell | 3,847 | $23.38 | $90.0K | 19,912 −16.2% of holding | |
| van Houte Hans | Chief Financial Officer | Sell | 2,845 | $23.38 | $66.5K | 44,927 −6% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 11,008 | $23.56 | $259.4K | 13,579 −44.8% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 28,935 | $20.06 | $580.5K | 13,579 −68.1% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell 10b5-1 | 5,394 | $20.00 | $107.9K | 115,005 −4.5% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 8,148 | $16.60 | $135.3K | 13,579 −37.5% of holding | |
| van Houte Hans 2 fills | Chief Financial Officer | Sell 10b5-1 | 14,055 | $16.60 | $233.3K | 38,174 −26.9% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 8,148 | $16.96 | $138.2K | 18,305 −30.8% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 5,394 | $16.76 | $90.4K | 26,453 −16.9% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell | 3,214 | $16.65 | $53.5K | 120,399 −2.6% of holding | |
| Ring Christine | Chief Legal Officer | Sell | 3,214 | $16.65 | $53.5K | 31,847 −9.2% of holding | |
| van Houte Hans | Chief Financial Officer | Sell | 2,388 | $16.65 | $39.7K | 51,647 −4.4% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 8,148 | $15.24 | $124.1K | 26,453 −23.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.